Last reviewed · How we verify
NCT06978595
Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies
trial in Colorectal Carcinoma in 8,171 participants. Completed in 30 December 2021.
30 December 2021
Quick facts
| Lead sponsor | asmaa salama ibrahim |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8,171 |
| Start date | 1 January 2000 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across Egypt |
Conditions studied
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
- Cancer — all drugs for Cancer →
- Signet Ring Adenocarcinoma of the Colon — all drugs for Signet Ring Adenocarcinoma of the Colon →
Sponsor
asmaa salama ibrahim
Who can join
Eligibility, any sex, with Colorectal Carcinoma or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This original research investigates the critical issue of gastrointestinal (GI) second primary malignancies (SPMs) in patients with signet ring cell carcinoma (SRCC), a rare and aggressive subtype of colorectal cancer. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, the investigators assessed the risk of GI SPMs, particularly within 2-11 months post-SRCC diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06978595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Carcinoma
Currently open trials in the same condition.
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis · Phase 2 · recruiting
- NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07192068 — Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration · Phase 2 · recruiting
Other asmaa salama ibrahim trials
Trials by the same sponsor.
- NCT06620926 — Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma · completed
- NCT06659224 — The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma · completed
- NCT06662734 — Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies · completed
- NCT06619535 — Sepsis As a Cause of Death Among Elderly Cancer Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06978595 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by asmaa salama ibrahim
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing